A bout 10 years ago we discovered that bubbling nitric oxide (NO) gas into KrebsRinger bicarbonate solution containing isolated precontracted strips of bovine coronary artery caused a rapid and pronounced, but transient, relaxant response that was antagonized by oxidized hemoproteins, such as methemoglobin, and by methylene blue.
A bout 10 years ago we discovered that bubbling nitric oxide (NO) gas into KrebsRinger bicarbonate solution containing isolated precontracted strips of bovine coronary artery caused a rapid and pronounced, but transient, relaxant response that was antagonized by oxidized hemoproteins, such as methemoglobin, and by methylene blue.
1 NO activated soluble guanylate cyclase prepared from coronary artery; this response was inhibited by methemoglobin, methylene blue, and ferricyanide. The observation that lipophilic methylene blue, but not the charged ferricyanide, antagonized vascular relaxant responses to NO suggested that NO interacts with intracellular smooth muscle receptors to cause relaxation. Moreover, the findings that nitroprusside and nitrosoguanidine, known to release NO in biological fluids, 2 " 4 caused arterial relaxation that was antagonized by methylene blue but not by ferricyanide or methemoglobin were consistent with the view that intracellular NO is the reactive intermediate. Although the pharmacological implications of these original findings were clear, the physiological relevance of such observations for NO and cyclic GMP remained elusive for several years.
Shortly after the studies on NO were conducted, Furchgott and Zawadzki 5 discovered that acetylcholine-elicited relaxation of isolated arterial preparations is dependent on the presence of an intact endothelial cell layer. These investigators showed that acetylcholine interacts with muscarinic receptors on endothelial cells to stimulate the release of one or more substances that cause relaxation of the underlying smooth muscle. An attractive hypothesis was offered that this relaxing substance might be a lipoxygenase product of arachidonic acid 5 -6 that stimulates cyclic GMP formation. 6 Furchgott and coworkers 6 recognized that soluble guanylate cyclase can be activated by free radicals including NO and that various nitrovasodilators may relax smooth muscle by release or generation of NO as reported by Murad and coworkers. 7 The 8-bromo analogue of cyclic GMP had been previously demonstrated to relax nonvascular as well as vascular smooth muscle.*-Furchgott and coworkers went on to propose that the unstable relaxing substance also is responsible for the arterial relaxant responses to bradykinin, histamine, ATP, ADP, and A23187. The relaxing substance was termed endotheliumderived relaxing factor (EDRF) shortly thereafter.
Back in 1981 we had not entertained the thought that EDRF could be NO. Efforts were directed toward elucidating the mechanisms by which organic nitrate and nitrite esters, inorganic nitrite, and nitroso compounds cause relaxation of arterial and venous smooth muscle. Evidence was obtained that these vasodilators either spontaneously release NO in aqueous solution or react rapidly with thiols to form chemically unstable 5-nitrosothiols. Based on these observations 12 - 19 and those of others who first demonstrated the direct activation of soluble guanylate cyclase by NO and nitroso compounds, 4 -20 -22 the hypothesis was proposed that lipophilic vasodilators such as glyceryl trinitrate, isoamyl nitrite, nitroprusside, and related agents must first penetrate vascular smooth muscle cells and react with free thiols to generate unstable 5-nitrosothiols, and that the 5-nitrosothiols stimulate cyclic GMP formation and cause vascular smooth muscle relaxation. 19 In retrospect, in view of the chemical instability of the 5-nitrosothiols, it is likely that NO is the common active species as proposed earlier. 4 In the midst of the above studies, we discovered that NO and vasodilators that generate NO were potent and marked inhibitors of human platelet aggregation, and that inhibition of platelet aggregation was associated with large and rapid increases in platelet cyclic GMP levels. 23 In addition to preventing the onset of platelet aggregation, NO caused platelet disaggregation that was preceded by cyclic GMP accumulation. These actions of NO were mimicked by the addition of 8-bromo cyclic GMP and were inhibited by hemoglobin. On the basis of these observations, we extended the earlier view that NO is the active species of several vasodilators, 4 in this case inhibiting platelet aggregation. 23 Similarly, cyclic GMP appeared to act as a second messenger in expression of the inhibitory action of NO on platelet function. 23 This initial hypothesis was strengthened by the further observations that 5-nitrosothiols activated platelet soluble guanylate cyclase by heme-dependent mechanisms, elevated platelet cyclic GMP levels, and inhibited platelet aggregation. 24 A short time after this laboratory and that of Furchgott noted the remarkable similarities in biological properties between EDRF and NO (individual talks presented at the Fourth Symposium on Mechanisms of Vasodilatation, Rochester, Minnesota, July 11, 1986), EDRF distinct from prostacyclin was reported to inhibit platelet aggregation 25 and was suggested to be pharmacologically and chemically identical to NO. 26 - 31 Throughout this review the term EDRF is used to signify the specific endothelium-derived relaxing factor first described by Furchgott and Zawadzki, 5 which may be NO or a labile nitroso compound. 26 - 31 A previous review from this laboratory addressed the pharmacology of NO and cyclic GMP on vascular smooth muscle. 32 The present review addresses the pharmacology of NO, EDRF, and cyclic GMP in blood vessels and platelets; the isolation and identification of EDRF as NO; and the formation, release, and metabolism of endothelium-derived NO (EDNO).
Pharmacology of Nitric Oxide in Blood Vessels

Direct Relaxant Action of Nitric Oxide in Artery and Vein
Vascular smooth muscle relaxants like glyceryl trinitrate, nitroprusside, inorganic nitrite, azide, hydroxylamine, and nitroso compounds not previously tested for relaxant effects activated soluble guanylate cyclase and elevated cyclic GMP levels in various mammalian tissues.
4 -8 -20 -22^3 -4 * NO gas was found to activate soluble guanylate cyclase and elevate cyclic GMP levels 4 -21 ' 22 and was suggested to be the common factor involved in enzyme activation by nitroprusside, nitrites, organic nitrates, nitroso compounds, azide, and hydroxylamine. 4 .7 . 8 , 21 , 2236 . 40 These observations led us to ascertain whether NO itself could cause vascular smooth muscle relaxation. NO gas and nitrosoguanidine compounds relaxed precontracted helical strips of bovine coronary artery, 1 -13 and this novel observation was extended to include chemical agents related to N O . --. * These observations were consistent with the conclusion that cyclic GMP may be involved in vascular smooth muscle relaxation elicited by specific pharmacological intervention. The well-known transient hypotensive actions of some of the above vasodilators were consistent with the lipophilic and very unstable properties of NO and with the view that NO can be released or generated from nitroprusside, nitrite, isoamyl nitrite, glyceryl trinitrate, nitrosoguanidines, and related agents.M.15.49-52 xhe longer-lasting response of glyceryl trinitrate was attributed to the concept that this lipophilic ester permeates the cell and continuously generates NO intracellularry. 19 In an attempt to find antagonists of NO, advantage was taken of previous reports that hemoglobin and methylene blue are inhibitors of guanylate cyclase activation by NO. 36 Oxidized and reduced forms of hemoglobin and myoglobin, and methylene blue, inhibited coronary arterial relaxation elicited by NO but not by catecholamines. 48 In these early studies we did not fully appreciate that commercially available hemoglobin and myoglobin were primarily in their oxidized forms. It is clear from the work of others that the reduced hemoproteins are more potent than their oxidized forms in inhibiting the actions of NO and nitrovasodilators on guanylate cyclase5 3* and on vascular smooth muscle. We have since made similar observations for NO. We have been unable to observe inhibition by any of these hemoproteins of the relaxant effects of nitroprusside, organic nitrate esters, and nitrosoguanidines, whereas methylene blue has been inhibitory. Reduced as well as oxidized hemoproteins react with and bind to NO, forming a relatively stable nitrosyl-hemoprotein complex that cannot penetrate the plasma membrane. Organic nitrate and nitrite esters and nitroso compounds are lipophilic substances and release or generate NO within the cells. Methylene blue is a vital biological stain that by definition penetrates the cell membrane. Therefore, hemoproteins cannot antagonize the effects of NO liberated intracellularly, whereas methylene blue c a n . --' ' -Similarly, the highly charged inorganic species ferricyanide, which is an oxidant and inhibits guanylate cyclase activation by NO, as does methylene blue, cannot inhibit the relaxant effect of NO because the ferricyanide cannot enter the cell to interact with the enzyme.
Mechanisms of Relaxation Caused by Nitrates, Nitrites, and Nitroso Compounds
Inorganic nitrite reacts in aqueous acid to form nitrous acid and NO. Inorganic nitrite is a weak activator of soluble guanylate cyclase 4 and is a well-known but weak vasodilator. Free sulfhydryls or thiols, such as cysteine and glutathione, substantially potentiate guanylate cyclase activation by nitrite and isoamyl nitrite.
13 -16 -47 Thiols markedly decrease the stability of nitrites by promoting the formation of NO. Nitrosoguanidiaes also react with thiols in aqueous solution to liberate NO.
14 Therefore, enhanced formation of NO could explain the thiol-enhanced activation of guanylate cyclase by these agents. We believed that NO reacted with thiols to form a third compound. This interpretation was supported by reports that thiols react with NO, nitrous acid, or acidic solutions of sodium nitrite to form 5-nitrosothiols or thionitrites. 49 ' S4 ' 55 These 5-nitrosothiols are very unstable, especially in solid form, and spontaneously decompose to yield NO and the corresponding disulfide. The only 5-nitrosothiol that we have found to be stable in the solid form is 5-nitroso-A^-acetylpenicillamine, but in aqueous solution it readily decomposes to release NO.
19
Several 5-nitrosothiols were synthesized and found to activate soluble guanylate cyclase from various tissues, and enzyme activation was inhibited by methylene blue, ferricyanide, or hemoproteins.
14 -16 -19 -56 - 61 Subsequent experiments revealed that nitroprusside, nitrosoguanidines, glyceryl trinitrate, and isoamyl nitrite could react readily with certain thiols to form the corresponding 5-nitrosothiols. 19 Interestingly, the chemical reaction involving glyceryl trinitrate, 19 as well as the activation of soluble guanylate cyclase by glyceryl trinitrate, 16 occurred only with cysteine. Other thiols including .N-acetylcysteine or even homocysteine could not substitute for cysteine, but the L and D isomers of cysteine produced equivalent effects. Further experiments showed that intravenous administration of a series of 5-nitrosothiols elevated tissue levels of cyclic GMP and produced potent and marked vasodilatory effects in anesthetized cats. The profile of hemodynamic effects of the 5-nitrosothiols was virtually identical to that of nitroprusside or glyceryl trinitrate. The onset (immediate) and duration (1-3 minutes) of the hypotensive responses were similar, and little or no change in the cardiac output accompanied the drop in systemic arterial pressure. Vasodilator responses were not antagonized by propranolol, indomethacin, or antihistaminic agents.
On the basis of the above observations, 5-nitrosothiols were proposed to be active intermediates in expressing the vascular smooth muscle relaxant action of organic nitrate and nitrite esters, inorganic nitrite, nitroprusside, and nitrosoguanidines. 19 It is more likely, however, that NO is the final active species as proposed earlier because 5-nitrosothiols are very unstable, especially at physiological pH and temperature, and spontaneously release NO. Thus, NO can activate guanylate cyclase in the absence of added thiol, and because enzyme activation by NO or 5-nitrosothiols requires the formation of nitrosyl-heme (attached to guanylate cyclase), it is conceivable that the 5-nitrosothiols serve as a readily available source of NO, which subsequently causes enzyme activation. Figure 1 is a schematic diagram of some proposed mechanisms of vascular smooth muscle relaxation elicited by nitrovasodilators; it is a19 modification of an earlier published schematic in which 5-nitrosothiols were represented as the active intermediate species.
Chronic administration of glyceryl trinitrate to humans can lead to the development of tolerance with little or no cross-tolerance to nitroprusside. 
Needleman and coworkers
62
-63 demonstrated the requirement of tissue -SH groups for arterial relaxation elicited by organic nitrate esters, nitroprusside, and related vasodilators and argued that glyceryl trinitrate oxidizes -SH groups to -SS groups and that the latter have a lower affinity than the former for organic nitrates. Appreciable crosstolerance to nitroprusside or nitrite does not develop, presumably because they interact with a different population of -SH groups, a view supported by the findings that their relaxant effects can be abolished by thiol alkylating agents. More recent studies were confirmatory and showed that the development of tolerance to vascular smooth muscle relaxation elicited by gryceryl trinitrate is accompanied by a concomitant development of tolerance to the cyclic GMP-accumulating action of glyceryl trinitrate.
64 -6 * Vascular tolerance to glyceryl trinitrate was not associated with appreciable cross-tolerance to nitroprusside or 8-bromo cyclic GMP.
66
In their original studies, Needleman and coworkers 62 -63 showed that the responsiveness of tolerant arterial smooth muscle to glyceryl trinitrate could be restored by treatment of arterial tissue with sulfhydryl reducing agents. This is consistent with the proposal that organic nitrate esters require the presence of cysteine for generation of S-nitrosocysteine and NO to cause vascular smooth muscle relaxation. 19 Moreover, arterial and venous strips rendered tolerant to the actions of glyceryl trinitrate are still fully responsive to S-nitrosothiols and NO.
32
Recent clinical studies have supported the above interpretations by revealing that intravenous Nacetylcysteine improved the responsiveness of tolerant patients to glyceryl trinitrate for treatment of angina or improvement of coronary sinus blood flow.-Additional studies have supported7277 this view in artery or v e i n , -and one study showed that NO formation from organic nitrate esters is catalyzed by cysteine and that this accounts for the capacity of the nitrates to activate soluble guanylate cyclase and cause vascular smooth muscle relaxation. 40 showed that the presence of heme was obligatory for guanylate cyclase activation by NO and by chemical agents that release or generate NO such as nitroprusside, inorganic nitrite, unstable nitrosoguanidines, azide, and hydroxylamine. These investigators concluded that thiols serve to reduce heme iron to the ferrous state and facilitate the subsequent reaction between NO and heme to form the paramagnetic species, nitrosyl-heme (NOheme), which is the active species responsible for the activation of guanylate cyclase by N O . -The above conclusions were supported by the subsequent observations that soluble guanylate cyclase purified from mammalian tissues is a hemoprotein that contains stoichiometric amounts of heme and that enzyme-bound heme is required for enzyme activation by N O . ---The enzyme also contains copper, although the role of copper in enzyme catalysis is not known.
Mechanism of Guanylate
The molecular mechanism by which NO-heme activates soluble guanylate cyclase is unknown but appears to be identical to that of protoporphyrin DC. 84 This may explain, at least in part, why vascular smooth muscle relaxation elicited by arachidonic acid is more complicated and somewhat different than that elicited by acetylcholine or NO.
32
- 86 
Pharmacology of Nitric Oxide in Platelets Direct Inhibitory Action on Platelet Aggregation
Early studies suggested that cyclic AMP was involved in inhibition of platelet aggregation and associated functions, 87 ' 88 whereas cyclic GMP levels increased during aggregation elicited by arachidonic acid, prostaglandin precursors, collagen, serotonin, and ADP, 89 -92 thereby suggesting that cyclic GMP might be involved in causing platelet aggregation. Platelet aggregation and secretion, however, could be dissociated from platelet cyclic GMP accumulation.-Moreover, ascorbate, nitroprusside, nitrosoguanidines, and azide were reported to elevate platelet cyclic GMP levels without provoking platelet aggregation or the release reaction.-Indeed, nitroprusside was observed to inhibit platelet aggregation. ' In 1981 NO, nitroprusside, nitrosoguanidines, and cigarette smoke were reported to inhibit the aggregation of human platelets, and this action was closely associated with platelet cyclic GMP accumulation.
23
NO also activated platelet-soluble guanylate cyclase and elevated platelet cyclic GMP levels. In addition to attenuating aggregation, NO and related agents were effective in disaggregating platelets, and this was again associated with platelet cyclic GMP accumulation. The inhibitory effects of NO on platelet function were antagonized by hemoproteins and methylene blue. Inhibition of platelet aggregation was observed also with the 8-bromo analogue of cyclic GMP. Thus, we postulated that cyclic GMP was involved in mediating inhibitory rather than stimulatory influences on human platelet function.
Similar Inhibitory Action of S-Nitrosothiols and Related Vasodilators
S-Nitrosothiols may serve as active intermediates not only for vasodilation but also for inhibition of platelet aggregation elicited by nitrovasodilators.
24
Synthetic S-nitrosothiols were found to mimic the actions of NO on platelet function and caused disaggregation of platelets that had been aggregated, while concomitantly elevating platelet cyclic GMP levels. Purified platelet-soluble guanylate cyclase was markedly activated by S-nitrosothiols in a heme-dependent manner. Although organic nitrate esters were reported to inhibit platelet function, 99 we have not been able to observe any antiaggregatory effects on washed human platelets. However, partial inhibition of platelet aggregation by glyceryl trinitrate and isosorbide dinitrate does occur in the presence of added cysteine. Moreover, partial inhibition of platelet aggregation occurs in platelet-rich plasma, and this effect is enhanced by added cysteine. Thus, it is conceivable that organic nitrate esters must first be metabolized to a nitroso compound or NO and that such a reaction cannot occur in platelets as it does in vascular smooth muscle. Further studies on the metabolism of organic nitrate esters in platelets and plasma are necessary to resolve this question.
Mechanism of Action of Nitric Oxide on Platelets
The mechanism by which NO inhibits platelet aggregation is the same mechanism by which NO relaxes vascular smooth muscle. NO is a very lipophilic molecule that readily permeates the plasma membrane and complexes with the heme group of soluble guanylate cyclase. The resulting NO-heme complex activates guanylate cyclase as discussed above and elevates platelet cyclic GMP levels. Nitroprusside, nitrosoguanidines, and related agents may release or generate NO or may react with thiols such as cysteine and glutathione to form S-nitrosothiols, which may either directly or indirectly, through the spontaneous release of NO, activate guanylate cyclase and inhibit platelet aggregation. The mechanism by which cyclic GMP inhibits platelet aggregation is unknown, but may be attributed to a decrease in intracellular free calcium concentration.
Regulation of Platelet Function
Endogenous factors that raise platelet cyclic GMP levels could play a physiological role as negative feedback modulators of platelet function. Until the discovery that NO occurs in vascular endothelial cells, prostacyclin was viewed as the principal endogenous inhibitor of platelet function. 100 -103 Agents or conditions that stimulate prostacyclin formation in vascular endothelial cells likely prevent platelet aggregation at the site of prostacyclin release from the vascular endothelium. The mechanism appears to be a prostacyclin-mediated activation of platelet adenylate cyclase with consequent intracellular platelet accumulation of cyclic AMP.
-102
It is now of great interest that not only prostacyclin but also NO is formed in the vascular endothelium and that NO and prostacyclin elicit similar effects on platelets. Moreover, cyclic AMP and cyclic GMP appear to play similar roles in inhibiting platelet function. Similarly, both cyclic nucleotides appear to mediate the same ultimate inhibitory action on vascular smooth muscle contraction. The physiological and pathophysiological implications of such dual mechanisms involving.cyclic GMP and cyclic AMP are intriguing. Extracellular or intracellular factors, respectively, may be capable of attenuating both platelet aggregation and vascular smooth muscle contraction by elevating cyclic AMP or cyclic GMP levels. Moreover, extracellular lipophilic factors that gain entry into the cells can directly influence soluble guanylate cyclase activity and thereby modulate platelet aggregation and vascular smooth muscle tone.
More recently, studies from Moncada's laboratory 103 have further characterized the actions of NO on platelets. The antiaggregatory activity of NO was potentiated by M&B 22,948, a selective inhibitor of cyclic GMP phosphodiesterase, and by superoxide dismutase (SOD), whereas the effects were antagonized by hemoglobin and ferrous ion. 30 The adhesion of human platelets to monolayers of bovine endothelial cells in culture was inhibited by NO but not by prostacyclin, and this effect was abolished by hemoglobin, potentiated by SOD, and unaffected by inhibitors of prostacyclin formation. The antiaggregatory effects of prostacyclin and NO occurred in a synergistic manner, and the authors postulated that interactions between prostacyclin and NO released by the vascular endothelium play a role in the homeostatic regulation of platelet-vessel wall interactions.
Actions and Properties of EDRF Mediation of Endothelium-Dependent VasodUation
Acetylcholine elicited endothelium-dependent relaxation of precontracted strips of rabbit aorta in a manner that was antagonized by atropine but not by indomethacin or aspirin and was diminished by potassium, quinacrine, eicosatetraynoic acid (ETYA), and anoxia. 5 The authors postulated, on the basis of a tissue "sandwich" technique, that acetylcholine stimulates the release of a relaxing factor from vascular endothelial cells. Chemically diverse substances such as the calcium ionophore A23187; histamine; serotonin; purines such as ATP and ADP; porypeptides such as bradykinin, substance P, and thrombin; and fatty acids such as arachidonic acid and related substances were subsequently found to relax arterial smooth muscle by similar mechanisms (see Reviews 106 -108 ). Most of the arterial relaxants failed to relax vein. Acetylcholine and bradykinin cause endothelium-dependent relaxation of bovine pulmonary artery, whereas only bradykinin relaxes bovine pulmonary v e i n . -Bradykinin stimulates the release of EDRF from both perfused artery and vein, whereas acetylcholine stimulates EDRF release only from perfused artery. It appears that venous endothelial cells do not possess muscarinic receptors. The difference does not lie with the vascular smooth muscle since arterial EDRF released by acetylcholine caused marked relaxation of strips of endothelium-denuded vein.
Demonstration of EDRF Release
The unequivocal release of EDRF was demonstrated by bioassay. 115 - 116 Perfused rabbit aorta and canine femoral artery released EDRF even in the absence of added endothelium-dependent vasodilators, and the half-life of the released EDRF was about 6-7 seconds. Other studies also revealed that an unstable EDRF could be released from perfused arterial segments. 117118 The bioassay cascade technique, originally developed by Sir John Vane for studies on the release and identification of biologically active substances, was then applied to perfused cultured vascular endothelial cells grown on microcarrier beads in studies designed to elucidate the properties of EDRF. 119 The advantages of the cascade approach of superfusing several vascular preparations arranged in series are that different vascular or nonvascular smooth muscle preparations may be studied concomitantly under the influence of a common EDRF, and that the short halflife of the EDRF can be easily appreciated and estimated. This bioassay cascade procedure has been used for study and comparison of the release of EDRF from intact perfused artery and vein.
Properties of EDRF
Based on the inhibitory actions of several inhibitors of arachidonic acid metabolism including quinacrine, nordihydroguaiaretic acid, ETYA, SKF-525A, iproniazid, metyrapone, and agents with similar effects on endothelium-dependent vascular smooth muscle relaxation, some investigators suggested that EDRF could be a lipoxygenase or cytochrome P-450 product of arachidonic acid metabolism.
120121 Independent studies from several laboratories showed that endothelium-dependent vascular smooth muscle relaxation was associated with cyclic GMP accumulation 109122 -' 25 and that methylene blue inhibited both relaxation and cyclic GMP accumulation. 109122 After finding that methylene blue inhibits endothelium-dependent as well as NO-elicited cyclic GMP accumulation and relaxation, we suggested that EDRF mimicks NO by activating soluble guanylate cyclase by calciumindependent mechanisms. Further support of the view that EDRF and NO are similar came when hemoglobin and methylene blue were reported to antagonize endothelium-dependent and glyceryl trinitrate-elicited relaxation in rabbit aorta.
In our hands, however, methylene blue but not hemoglobin antagonizes glyceryl trinitrate-elicited relaxation of bovine coronary artery and pulmonary artery and vein.
1131 M Using endothelium-intact rings of bovine pulmonary artery and vein, we found that such preparations generated and released a factor that directly activated soluble guanylate cyclase purified to homogeneity from bovine lung. Methylene blue inhibited the direct activation of enzyme without affecting the generation or release of EDRF from arterial and venous rings. Similar observations were made independently for EDRF released from other arterial preparations.
After finding that EDRF activates soluble guanylate cyclase, we suggested that EDRF may be an unstable nitroso compound related to NO. 128 The mechanism of activation of soluble guanylate cyclase by EDRF was examined and compared with the known mechanism for NO, and enzyme activation by arterial and venous EDRF was found to require heme. 28 These observations were consistent with the observations that EDRF and NO shared the property of reacting with the heme of hemoglobin to generate the nitrosyl-heme adduct of hemoglobin.
28
These findings explain why hemoglobin and myoglobin markedly antagonize endothelium-dependent relaxation 53 '-135 Methylene blue may owe part of its action to superoxide generation, since SOD partially blocked the inhibitory effect of methylene blue on arterial relaxation caused by EDRF.
Furchgott and coworkers 6 first described the attenuation of acetylcholine-elicited relaxant responses in rabbit aorta when potassium chloride was used instead of norepinephrine for precontraction of the tissue although equivalent magnitudes of contraction were produced. Other investigators made similar observations. 86 -112137 -' 41 In our experience, endothelium-dependent relaxant responses to high concentrations of relaxant in the presence of potassium-contracted vascular rings are only 10-15% of those obtained when either phenylephrine or U46619 is used to cause contraction.
Roles of Calcium and Magnesium
Calcium appears to be required for the generation and/or release of EDRF rather than for the direct smooth muscle relaxant action of EDRF. The early observations that A23187 caused endotheliumdependent relaxation led to the hypothesis that an increase in intracellular calcium concentration might be an early step in the sequence of reactions mediating the release of EDRF by acetylcholine and A23187. 6 In 1982 Singer and Peach 142 reported that extracellular calcium was required for maximal endothelium-dependent relaxant responses, and that verapamil and nifedipine attenuated such relaxant responses. Endothelium-dependent relaxation was markedly inhibited by the removal of calcium from the extracellular medium, 143 -146 and a bioassay procedure revealed that calcium is required for the production and/or release of an EDRF. 147 Further studies demonstrated the relation between endo- Unpublished observations from this laboratory indicate that in a bioassay cascade system, extracellular calcium is required for EDRF formation and/or release, and that both the calcium entry blocking agents like verapamil and nifedipine as well as dichlorobenzamil markedly antagonize endotheliumdependent relaxation. Peach and coworkers 155 reported that endothelium-dependent vasodilators cause an increase in intracellular free calcium concentration that is not abolished in the presence of EGTA or verapamil, and that the generation and/or release of EDRF from cultured aortic endothelial cells required extracellular calcium. These investigators concluded that endothelium-dependent vasodilators interact with endothelial cell receptors to cause an increase in intracellular free calcium attributed to the mobilization of both extracellular and intracellular calcium, and that calcium in some manner causes EDRF generation and/or release.
Experiments designed to elucidate the critical role of calcium in endothelium-dependent relaxation should include studies on magnesium because of the well-known mutually antagonistic influences of each of these cations in both cardiac muscle 157 and vascular smooth muscle. 15 *- 160 Extracellular magnesium was believed to be required for endothelium-dependent relaxation, 161 thereby lending support to an earlier hypothesis that dietary deficiency of magnesium may be an important factor in the etiology of coronary vasospasm. 162 The sudden or acute removal of extracellular magnesium, however, was shown to elicit endothelium-dependent and calcium-dependent relaxation of coronary artery. 163 Magnesium deficiencyinduced relaxation was inhibited by calcium removal and dichlorobenzamil but not nifedipine. Endotheliumdenuded coronary arterial preparations contracted in response to magnesium removal, and contractions were inhibited by nifedipine but not by dichlorobenzamil. Ku and Ann speculated that circulating magnesium has a dual effect in modulation of coronary tone. Healthy coronary arteries may dilate, whereas diseased or endothelium-damaged coronary arteries may constrict in response to hypomagnesemia.
Recent studies from this laboratory indicate that removal of magnesium from the extracellular medium causes transient endothelium-and calcium-dependent relaxation of bovine intrapulmonary artery and vein, and acetylcholine (artery) and bradykinin (vein) still cause pronounced relaxation. 164 This transient endothelium-dependent relaxation is accompanied by an increase in cyclic GMP levels. Oxyhemoglobin, methylene blue, and superoxide anion abolished endothelium-dependent relaxation and cyclic GMP accumulation, as did endothelium denudation or the removal of extracellular calcium, whereas responses were markedly potentiated by SOD. The sudden removal of magnesium from the medium perfusing a segment of intact artery or vein resulted in a greatly increased formation and/or release of EDRF, both in the absence and in the presence of added endotheliumdependent vasodilators. 164 In contrast to magnesium, the removal of calcium from the perfusion medium resulted in almost complete abolition of EDRF formation and/or release, and readdition of calcium to the perfusion medium fully restored the capacity of endothelium-dependent relaxants to release EDRF. These observations agree with those of Ku and Ann 163 that magnesium deficiency causes endotheliumdependent relaxation. In addition, we have found that in the absence of extracellular magnesium, the subsequent addition of magnesium causes endotheliumindependent relaxation that is unaltered by oxyhemoglobin or methylene blue and is not associated with changes in cyclic GMP or cyclic AMP levels. The relaxant effects of magnesium may be attributed to an unexplained antagonistic action of magnesium on calcium, thereby preventing the interaction between calcium and the contractile proteins. The result of this would be decreased smooth muscle contraction or decreased smooth muscle tone.
These observations indicate clearly that magnesium and calcium interact with one another at the extracellular and/or intracellular level to produce antagonistic influences on at least several biological processes associated with changes in vascular smooth muscle tone. Calcium is required for and mediates the formation and/or release of EDRF, whereas magnesium opposes this action of calcium. Thus, the sudden removal of inhibitory magnesium results in a transient endothelium-dependent relaxation attributed to enhanced formation and/or release of EDRF. But in endothelium-damaged vessels, the removal of magnesium causes calcium to express its maximal contractile action. Similarly, whether the vascular endothelium is healthy or damaged, an increase in the concentration of magnesium causes endothelium-independent relaxation, and this is attributed to the opposing influence of magnesium on calcium-elicited contraction. Neither the physiological nor pathophysiological implications of these observations are as yet clear, but vascular disorders such as vasospasm may occur in diseased coronary artery or cerebral artery or other diseased blood vessels when the magnesium concentration in the circulating blood is lowered.
Inhibitory Action of EDRF on Platelet Aggregation
In 1981 we reported that NO was a potent and marked inhibitor of human platelet aggregation, that this effect was associated with a rapid and pronounced but transient elevation in platelet cyclic GMP levels, and that both responses were antagonized by hemoglobin. 23 Five years later, in 1986, EDRF was reported to inhibit platelet aggregation.
Perfused rabbit aorta was shown to release a substance^) in response to acetylcholine in the presence of indomethacin that relaxed strips of endothelium-denuded aorta and inhibited arachidonic acid-induced aggregation of rabbit platelets. Endothelium-intact but not denuded arterial rings inhibited human platelet aggregation in a manner that was inhibited by hemoglobin and enhanced by SOD, and EDRF from cultured human umbilical vein endothehal cells inhibited platelet aggregation by mechanisms that were antagonized by gossypol, methylene blue, or oxyhemoglobin.
Radomski and coworkers 30 reported that EDRF released from cultured porcine aortic endothehal cells inhibited human and rabbit platelet aggregation in the same manner as that observed for NO. The antiaggregatory activities of EDRF and NO but not of prostacyclin were potentiated by M&B 22,948 and by SOD and were inhibited by hemoglobin and ferrous ion. Thus, prostacyclin and EDRF (NO) are distinct endothelium-derived substances possessing vasodilator and antiplatelet actions. Subsequent reports from the same group revealed that EDRF or NO and prostacyclin produced synergistic antiaggregatory effects on platelets, 105 and that NO but not prostacyclin inhibited platelet adhesion to vascular endothehal cells. 104 These authors suggested that prostacyclin and EDRF or NO may regulate plateletvessel wall interactions in vivo at much lower concentrations than those detectable by nonbioassay techniques. One possible explanation for the clinical observations that large doses of aspirin and related drugs that inhibit prostacyclin formation do not provoke thromboembolic disorders is the continued antiplatelet actions of endothelium-derived NO.
Isolation and Identification of EDRF as Nitric Oxide Earlier Views on the Chemical Nature of EDRF
On the basis of the inhibitory actions of ETYA and quinacrine, Furchgott and coworkers 5 ' 6 believed that EDRF might be a product of the action of lipoxygenase on arachidonic acid. Free radicals and unsaturated fatty acids or their oxidation products were reported to activate soluble guanylate cyclase and could be inhibited by ETYA, quinacrine, and nordihydroguaiaretic acid.
-
167
- 169 Moreover, the free radical scavenger hydroquinone inhibited endotheliumdependent relaxation.
6 However, endotheliumdependent relaxation elicited by acetylcholine and other endothelium-dependent relaxants was not always inhibited by quinacrine in various arteries and species. 106 Furchgott and coworkers 107 . 125 expressed further doubts that EDRF is derived from arachidonic acid. Arachidonie acid caused endothelium-dependent and endothelium-independent relaxation, and the former result was variably antagonized by indomethacjn.86,106.121,125,170,171 Evidence had accumulated that arachidonic acid could serve as a substrate for hepatic microsomal cytochrome P-450, 172 and on the basis of inhibitory effects of cytochrome P-450 inhibitors, EDRF was suggested to be a cytochrome P-450 product of arachidonic acid.
121
- 170 This hypothesis was weakened when fatty acids other than arachidonic acid were found to elicit endotheliumdependent relaxation, 125 and additional experiments argued against the hypothesis that arachidonic acid was a precursor of EDRF. 178 reported that the cleavage of phospholipids could be involved in EDRF formation. Melittin, a phospholipase A 2 activator, elicited endothelium-dependent arterial relaxation, and inhibition of acyl-CoA:lysolecithin acyltransferase activity by the sulfhydryl reagent thimerosal was associated with endothelium-dependent relaxation. The authors concluded that the cleavage of phospholipids and release of free fatty acids is involved in, or closely related to, the process of EDRF formation. Subsequently, the polyphenolic antioxidant and lipoxygenase inhibitor gossypol was reported to inhibit the generation and/or release but not the direct relaxant effect of E D R F . --Recently, however, Forstermarm et al noted that most of the inhibitors of lipoxygenase and cytochrome P-450 produce highly inconsistent and nonselective effects on relaxant responses to various endotheliumdependent v a s o d i l a t o r s -' ' and concluded that such compounds are of limited value for characterization of the mechanism of EDRF production. Nevertheless, it appears that phospholipid metabolism is closely associated with EDRF formation/ release, perhaps attributed to elevated intracellular calcium levels.
Similarities Between EDRF and Nitric Oxide
This laboratory 183 and that of Furchgott 184 independently proposed in 1986 that EDRF is NO or a related nitroso compound. These proposals were based on indirect observations on the similar pharmacological properties of EDRF and NO. The most convincing finding for this laboratory to suggest that EDRF behaves like NO was the activation of purified soluble guanylate cyclase by EDRF. 110 Figure 2 illustrates that EDRF released from artery and vein is indistinguishable from NO superfused over arterial or venous strips. The similarity in chemical reactivity between hemoproteins and EDRF or NO is described in the next section.
One major dissimilarity between EDRF and NO was reported by one group to be that only NO is capable of relaxing nonvascular smooth muscle.
187~189
EDRF released from cultured arterial endothelial cells relaxed superfused precontracted arterial rings but failed to relax precontracted strips of guinea pig trachea and uterus and rabbit teniae coli. Sodium nitroprusside, which releases NO in solution, 19 caused greater relaxation of arterial than tracheal smooth muscle, but other nonvascular smooth muscle preparations were not examined. 187 NO relaxed vascular and teniae coli smooth muscle but not other smooth muscle preparations, 188 and anion exchange resins trapped and thereby prevented the arterial relaxant action of EDRF but not NO. 189 The reason for the different behavior of EDRF and NO in anion exchange resins is unresolved, but differences in column flow rates could account for varying recoveries of labile compounds from the column. Recent studies from this laboratory, in direct contrast to those discussed above, indicated clearly that both vascular and nonvascular smooth muscle preparations relax in response to both EDRF and NO, and that the principal difference between the two types of smooth muscle is that vascular muscle is much more sensitive than is nonvascular muscle to the relaxant actions of EDRF and NO. With the bioassay cascade procedure, EDRF generated from bovine pulmonary artery or vein and from human umbilical vein was superfused over a cascade of strips consisting of both nonvascular and vascular smooth muscle and the responses were BothEDRF andNO those of superfused authentic NO. Both f o r m and NO i n and stimulated cyclic GMP i n in precontracted strips of bovine 
Acetylcholine (ACH) and bradykinin (BKN) were perfused through the arterial and venous segments, respectively, for 3 minutes. Oxyhemoglobin (HbOJ was superfused over the strips as indicated, and this was continued during perfusion with ACH or BKN and during superfusion with NO and GTN. Tracings from two of six separate experiments are illustrated (reproduced from Ignarro et al° with permission).
tracheal smooth muscle, rat stomach fundus, guinea pig ileum, rabbit teniae coli, and endotheliumdenuded bovine artery and vein, and tissue responses were inhibited by hemoglobin, methylene blue, or superoxide anion and were enhanced by SOD. The sensitivities of the various nonvascular smooth muscle preparations to EDRF paralleled those to NO, but vascular smooth muscle was from 10 to 100 times more sensitive than nonvascular smooth muscle to both relaxation and cyclic GMP accumulation elicited by EDRF and NO.
Another important observation that indicated the close similarity between EDRF and NO was the more recently reported inhibitory action of EDRF on platelet aggregation, 25 since NO was shown in 1981 to be a potent inhibitor of human platelet aggregation. 23 The countless number of pharmacological similarities in properties between EDRF and NO paved the way for the experiments leading to the chemical identification of EDRF.
Chemical Identification of EDRF
The chemical identification of EDRF was provided independently in 1987 by two laboratories. Palmer and coworkers 26 reported that EDRF released from cultured porcine aortic endothelial cells grown on microcarrier beads was NO as identified by the reaction between EDRF and ozone to yield a chemiluminescent product that was indistinguishable from the reaction product between authentic NO and ozone. The chemiluminescence technique is tedious and detects inorganic nitrite as well as NO gas. Reflux in acid at elevated temperatures converts nitrite to NO gas, and thus the contribution made by background nitrite must be subtracted from the measurement of total NO gas. Unstable nitroso compounds that liberate NO gas are also detectable.
Studies from this laboratory employing two different chemical approaches indicated that EDRF and NO were very closely related chemical species. 2728 First, hemoglobin was found to react with EDRF released from freshly isolated aortic endothelial cells in a manner that was identical for the same reaction involving NO. Under conditions of low oxygen tension and presence of reduced hemoglobin, NO is well known to react rapidly with the heme moiety of hemoglobin to yield the nitrosyl (or NO) adduct of hemoglobin. NO-hemoglobin possesses a distinct absorbance in the Soret region that can be easily distinguished from the absorbances of related hemoprotein adducts such as oxyhemoglobin, carboxyhemoglobin, or methemoglobin. EDRF reacted with hemoglobin under identical conditions to those employed for NO to yield the same NO-hemoglobin reaction product. In another study, the chemical identification of both arterial and venous EDRF as NO or a nitroso compound was made by use of the principle of NO-catalyzed diazotization of sulfanilic acid at acidic pH. EDRF released from perfused intact artery and vein was superfused over bioassay strips, collected in acidic medium, and then chemically assayed. The EDRF released from the vessels was indistinguishable, both chemically and pharmacologically, from the authentic NO superfused over the bioassay strips. The diazotization reaction, however, is not very sensitive and cannot distinguish among NO, acidic nitrite, and labile nitroso compounds. Thus, it is conceivable that EDRF is a labile nitroso species that spontaneously generates NO.
EDRF from artery and vein possessed the same half-life as NO (3-5 seconds), both EDRF and NO elevated cyclic GMP levels in the bioassay strips, and the relaxant responses of EDRF and NO were abolished by superoxide anion and enhanced by SOD.
These and other observations provided experimental evidence that at least one EDRF released from cultured porcine aortic endothelial cells, intact bovine pulmonary artery and vein, and freshly isolated bovine aortic endothelial cells is either NO or a chemically related unstable nitroso species.
2 *-31104105 " 0128183 Thus, in much the same manner that other potent pharmacological agents have been subsequently discovered to occur endogenously, NO, which was described as a potent vasodilator and inhibitor of platelet aggregation about 10 years ago, now appears to occur endogenously as one EDRF in mammalian blood vessels, and perhaps also in other cell types. The potent vasodilator glyceryl trinitrate, which has been used clinically for over a century, can be regarded to have an endogenous counterpart in NO since NO is the chemical species responsible for its vasodilator action.
Regulation of Vascular Smooth Muscle Tone by Nitric Oxide and Cyclic GMP
Basal Release of EDRF EDRF is continuously generated and/or released from endothelium-intact vascular preparations in the absence of added endothelium-dependent relaxing agents. An early clue for basal release of EDRF was the finding that tissue cyclic GMP levels were significantly higher in endothelium-intact than in denuded vascular preparations .*•'
-"" 191 • 192 Studies with hemoglobin and M&B 22,948 provided further indirect evidence for basal EDRF release. 191192 More direct evidence was derived from bioassay experiments in which basal release of EDRF was directly and easily observed.
27 " 3 -1191 " 1 '"). 1 " Cyclic GMP appears to mediate basal EDRF-elicited inhibition of contractile responses of rat arteries to a-adrenoceptor stimulation. 194 The tonic elevation of cyclic GMP levels appeared to exert a more pronounced inhibitory effect against contractions elicited by the partial agonist, clonidine, than against contractions elicited by the full agonist, norepinephrine. These findings helped explain earlier observations that contractile responses of some arteries to a-adrenoceptor agonists, especially selective a148193 2 -agonists, are enhanced by endothelium r e m o v a l . -The intrinsic stimulus for basal release of EDNO is not understood, but it is likely that endothelial cell membrane perturbations and calcium are intimately involved in basal EDNO generation and/or release.
Basal release of EDRF may vary considerably among vessel types and diameters and may be important in the regulation of intrinsic smooth muscle tone and contractile responsiveness. For example, greater basal release of EDRF appears to occur in bovine intrapulmonary artery and vein with smaller rather than larger diameters. 111 The smaller the diameter of the endothelium-intact rings, the higher the resting levels of cyclic GMP and the more difficult it is to induce and to maintain induced tone of rings mounted and equilibrated under opti-Ignarro Endothdium-Derived Nitric Oxide mal resting tensions. Normal contractile responses to phenylephrine can be restored by endothelium denudation or by addition of either hemoglobin or methylene blue. M&B 22,948 confers endotheliumlike properties on endothelium-denuded rings by allowing tissue cyclic GMP to accumulate and decreasing vascular tone.
Basal or spontaneous formation and/or release of arterial and venous EDNO may be important for the continuous modulation of vascular smooth muscle tone and platelet adhesion and aggregation. The combined actions of prostacyclin and EDNO could serve to prevent or counteract localized vasospasm and thrombus formation that could develop in response to factors released from vascular endothelium, activated platelets, and other blood cells.
Chemical and Biological Properties of Nitric Oxide as an Ideal Modulator of Local Blood Flow and Platelet Function
The chemical and biological properties of NO are well suited for a local modulator of blood flow and platelet function. The vascular endothelial cell origin of NO is ideal for the local immediate delivery of the unstable substance directly to the underlying smooth muscle as well as to the endothelial cell surface for interaction with adhering or nearby platelets. Its very small molecular size and lipophilic nature are highly conducive to the rapid diffusion of NO through cell membranes to reach the smooth muscle, endothelial cell surface, and intracellular platelet compartment. The chemically unstable nature of NO allows for truly local actions, as does the high capacity of NO to bind to and become sequestered by erythrocyte hemoglobin. The diffusible nature of NO may endow this biologically active molecule with the unique capacity to engage in cell-to-cell communication. In this manner, NO released locally from the vascular endothelium may quickly communicate with adjacent cells and cause them to act in concert to achieve a particular physiological or pathophysiological response. Interference with basal release of EDNO, which could result from local damage to the vascular endothelium, could cause increased platelet adhesion and increased intrinsic tone or responsiveness to endogenous contractile factors, particularly those derived from activated aggregating platelets. Evidence exists that this can occur in cases of atherosclerosis and balloon catheter-induced vascular intimal damage in the dog and s w i n e . -The chemical and biological properties of NO are compatible with a physiological role in mediation of reactive dilation, shear stress-induced dilation, or flow-dependent dilation. These different terms probably represent the same or similar processes and may be mediated by EDRF. This phenomenon, which is different from reactive hyperemia, was described recently in large epicardial coronary arteries in conscious dogs 201 and shown to be endothelium-dependent. 202 -209 It is likely that EDRF or NO mediates this vasodilation. The signaling mechanism associated with the stimulation of formation and/or release of EDRF is unknown but may be related to shear stress that could alter the physical or electrical properties of the endothelial cell membrane and thereby trigger an increase in intracellular free calcium concentration. Alternatively, hemodynamic shear stress and acetylcholine have recently been shown to activate an inwardly rectifying, potassium-selective current that could cause membrane hyperpolarization and vascular smooth muscle relaxation. 210 Whether or not EDRF causes vascular smooth muscle relaxation by mechanisms involving membrane hyperpolarization is presently controversialand needs further investigation in experiments designed to compare and contrast the actions of EDRF and authentic NO. It is also possible that one or more endothelium-derived hyperpolarizing factors distinct from EDRF or NO exists, and that the former modifies the action of the latter.
Role of EDRF as an Autacoid
Autacoids such as histamine, serotonin, bradykinin, and perhaps substance P and other polypeptides appear to function in pathophysiological states where they elicit local actions such as vasodilation, increased vascular permeability, stimulation of certain sensory nerve receptors, and related effects. Some of these effects are mediated by prostaglandins and EDRF. EDRF may function both in physiological and pathophysiological situations. Along more physiological lines, EDRF may play a role in modulation of normal resting vascular smooth muscle tone, mediation of reactive dilation or shear stress-induced dilation, or other autoregulatory blood flow adjustments involving acute alterations in oxygen tension, metabolic activity, and related factors. At least two pathological conditions in which a deficiency in EDRF formation and/or release may be implicated in provoking further cellular and tissue dysfunction are vasospasm and stroke. Clinical and arteriographic studies have shown that atherosclerotic human coronary arteries may be prone to spontaneous vasospasm and show increased sensitivity to spasm elicited by contractile substances such as ergonovine.-Recent studies suggest that attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries may be at least partially responsible for coronary vasospasm. Atherosclerosis has been associated with decreased release and/or action of EDRF in arteries.-Attenuated actions of EDRF by other mechanisms such as free circulating hemoglobin could conceivably provoke localized vasospasm and platelet aggregation.
Endotheliwn-Derived Contractile Factors
Vascular endothelial cells under various conditions including anoxia have been shown to contribute to or facilitate the contraction of vascular smooth muscle. 106.138,223-223 Q^g endothelium-derived con-tractile factor was described in an elegant report by Yanagisawa and coworkers. 226 These investigators isolated, identified, tested, and molecularly cloned the precursor to the contractile factor. The substance was derived from cultured porcine aortic endothelial cells and found to be a 21-residue vasoconstrictor peptide. This polypeptide, named endothelin, is a potent vasoconstrictor; the authors found that shear stress forces along the endothelial cells caused down-regulation of the expression of the proendothelin gene and speculated that flowdependent inhibition of endothelin production could contribute to endothelium-mediated, flow-induced vasodilation. The authors also speculated, on the basis of studies involving calcium and calcium channel antagonists, that endothelin may be an endogenous agonist of the dihydropyridine-sensitive calcium channels. The relations among the biological actions of EDRF, prostacyclin, and endothelin need to be elucidated for better understanding of the overall picture of the local control of blood flow and platelet function.
Formation, Release, and Metabolism of Nitric Oxide Formation and/or Release
In view of the fact that NO is a chemically unstable substance with a very short half-life, the assumption might be made that EDNO elicits its local actions immediately after synthesis. The chemical properties of NO are highly conducive to rapid diffusion of NO to nearby smooth muscle cells and platelets adhering to the intimal surface. The requirement of calcium and oxygen for endotheliumdependent relaxation might then be attributed to their necessity for NO formation and/or coupling of the extracellular relaxant-receptor interaction to NO formation. An alternative hypothesis is that NO is formed and stored within vascular endothelial cells and that interaction of endothelium-dependent vasodilators with selective endothelial cell membrane receptors triggers NO exocytosis or secretion in a calcium-and oxygen-dependent manner. NO may be stored in a different form within vesicles such as lysosomes in the presence of hydrogen ion and/or thiols. NO exists primarily as nitrous acid at acidic pH, and as more stable 5-nitrosothiols in the presence of thiols at acidic pH. Any slow leakage of the lipophilic nitrous acid or nitroso derivative out of storage granules could at least partially explain the mechanism of basal release of NO from vascular endothelial cells.
Although several different biological metabolic pathways for NO formation are known, none is yet known to occur in mammalian cells despite the findings that NO has been identified to exist endogenously in mammalian vascular endothelial cells. 26 -28 Possible pathways for NO formation might include enzymatic (nitrite reductase) or nonenzymatic (thiols and/or acidification) reduction of inorganic nitrite to NO. Sources of nitrite might include organic nitrate esters that can be enzymatically (nitrate reductase) or nonenzymatically (thiols) monodenitrated to nitrite. Another pathway could be the oxidation of certain amino groups derived from basic amino acids such as L-argjnine or related basic polypeptides containing L-arginine or L-lysine. The basic nitrogens may be oxidized to NO or to nitrite followed by conversion to NO. Another possibility is that a basic amino function could first be converted to ammonia, which could then be oxidized to NO. Recent evidence indicates that the inhibitory factor, possessing vasodilator properties, extracted from bovine retractor penis muscle is inorganic nitrite and that acidification results in formation of NO.
184
- 227 The extract is inactive until acidified, and the acid-activated form possesses the chemical and biological properties of NO. The extract may contain a NO-stabilizing substance, such as a thiol or sugar, that favors conversion of nitrite to NO. 227 Preliminary evidence exists that vasodilator activity indistinguishable from that of the inhibitory factor is extractable from cultured bovine aortic endothelial cells and vascular smooth muscle. 227 The role of nitrite in vascular smooth muscle tissue is unknown, but it may be an inactive oxidized metabolite of NO and thus serve to conserve the intracellular pool of NO by transport back to the endothelium and reconversion to NO.
Mammalian cells are capable of synthesizing nitrite and nitrate in the absence of any anaerobic microorganisms. Stuehr, Marietta, and coworkers 228 -232 have shown that murine macrophages synthesize nitrite and nitrate in response to activation by lipopotysaccharides, Calmette-Gu6rin bacillus (BCG) infection, rymphokines, and related factors and that T lymphocytes enhance this synthesis. Nitrite and nitrate may be involved in the cytotoxic actions of activated macrophages, perhaps by stimulating intracellular nitrosation reactions with the resulting Nnitroso compounds causing the cytotoxicity. Nitrite and nitrate are synthesized in a relatively constant ratio of 3:2, 231 but most of the nitrate formed could originally derive from nitrite as a result of oxidation of nitrite to nitrate by oxyhemoglobin. 230 Although no comment was made by the authors, it is conceivable that NO is also formed and oxidized to both nitrite and nitrate by oxyhemoglobin and oxymyoglobin. The nitrogens of nitrite and nitrate are derived exclusively from the terminal guanido nitrogens of L-arginine, which appears to be the precursor to nitrite/nitrate in activated mammalian macrophages. L-Arginine is required also for the expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells, and the nitrite derived from Larginine may be generated through the actions of an arginine deiminase producing L-citrulline and ammonia followed by oxidation of ammonia to nitrite. However, arginine deiminase does not appear to occur in mammalian cells, ammonia production and Ignarro Endothelium-Dertved Nitric Oxide L-arginine-dependent macrophage cytotoxicity do not correlate, and ammonia is not a precursor for nitrite/nitrate formation in activated macrophages. 232 Thus, another pathway is likely to be responsible for the oxidation of L-arginine to nitrite and nitrate, and NO is most likely an intermediate in this process. NO discharged from activated tissue macrophages could affect nearby vascular smooth muscle and platelets adhering to the vascular intimal surface. The net effect would be promotion of local vasodilation and increased blood flow to the macrophage-infiltrated tissue with minimal platelet aggregation and thrombus formation at such sites.
Other phagocytic cells or cells that mediate cytotoxic reactions may contain nitrite or NO for similar purposes of cytotoxicity and local modulation of blood flow and platelet function. Such a hypothesis is intriguing also because it implicates several different biological functions of just a single substance that has a biological half-life of only several seconds. Indeed, a recent study indicated that activated rat peritoneal neutrophils release an unstable chemical substance that relaxes isolated endothelium-denuded preparations of rat aorta. The properties of this neutrophil-derived relaxing factor were very similar to those of endothelium-derived NO in that relaxant responses were enhanced by SOD and low oxygen tension, inhibited by methylene blue, and unaltered by indomethacin. Further studies revealed that the neutrophil-derived relaxing factor stimulated cyclic GMP accumulation in vascular smooth muscle, relaxed vascular as well as nonvascular smooth muscle, and was most likely NO derived from inorganic nitrite.
Evidence was provided that L-arginine can serve as a precursor for EDNO in cultured porcine aortic endothelial cells. This conclusion was based on direct observations that endothelial cells utilized radiolabeted L-arginine ( I3 N in guanidino group) to generate IJ NO, as assessed by mass spectrometry, 239 and on indirect observations that structural analogues of arginine such as A^-monomethyl-L-arginine and L-canavanine antagonize endotheliumdependent relaxation. 240 Recent studies in this laboratory support the above observations. A high concentration (4 mM) of L-canavanine preincubated with vascular tissue for 3 hours was found to be necessary for moderate inhibition of endotheliumdependent relaxation (Figure 3) . A lower concentration (0.1 mM) of Tv^-monomethyl-L-arginine inhibited endothelium-dependent relaxation after only 5 minutes of preincubation with vascular tissue. Addition of 0.3 mM L-arginine caused a rapid and marked reversal of inhibition (Figure 3) . Neither inhibitor altered the relaxant responses to authentic NO. Additional bioassay experiments revealed that perfusion of intact pulmonary artery with either L-canavanine or A^-monomethyl-L-arginine inhibited the further formation of EDNO. These findings support the hypothesis that endogenous endothelium- derived L-arginine could serve as a natural precursor to EDNO. 239 Although it appears that NO can be formed from L-arginine, the biosynthetic pathway remains unknown. NO may be formed directly from one of the basic amino nitrogens of L-arginine, or NO may be formed from an intermediate generated from L-arginine such as an organic nitroso compound, ammonia, or nitrite. Moreover, larger molecules containing arginine or other basic amino acids could serve as precursors for EDNO. For example, recent experiments indicate that basic poryamino acids including poly-arginine, poly-lysine, and polyomithine cause endothelium-dependent arterial 241 and venous relaxation and cyclic GMP accumulation via the formation and release of EDNO. 242 The mechanism of this relaxation is unknown, but one possibility is that the basic nitrogen atoms of such polyamino acids are converted to NO or intermediate nitroso compounds.
Metabolism and Termination of Action
Chemical instability endows EDNO with one of the most important requisite properties of a local modulator or autacoid, namely, rapid termination of action so that the biological effect remains localized. The very short half-life of NO of only several seconds makes it unnecessary to demand other mechanisms of termination of action such as enzymatic degradation or reuptake mechanisms. In the spontaneous conversion of NO to nitrite and nitrate, it is conceivable that nitrite could be transported back into endothelial cells for conversion to NO. Although not demonstrated, such a pathway would conserve NO in addition to contributing to its termination of action. Another mechanism that may contribute to the termination of action and perhaps conservation of NO might be rapid binding to oxyhemoglobin. Such a reaction could serve to prevent lumenally released NO from eliciting vasodilation downstream. Moreover, NO would be rapidly oxidized to nitrite and nitrate in the presence of oxyhemoglobin. Finally, an additional mechanism of inactivation of NO might be the concomitant generation and release of superoxide anion from vascular endothelial cells, smooth muscle cells, and phagocytic cells. This reaction is very well known to occur in activated macrophages and neutrophils, and evidence exists that vascular endothelium 244 and smooth muscle can generate superoxide anion.
The Endogenous Nitric Oxide Receptor The endogenous receptor for NO is likely the heme moiety of soluble guanylate cyclase. NO interacts with guanylate cyclase-bound heme to form the nitrosyl-heme adduct or activated form of the enzyme. Enzyme interaction with EDNO is indistinguishable from that with authentic NO in vascular smooth muscle and platelets. Inhibition of enzyme activation by methylene blue causes decreased formation of mtracellular cyclic GMP, decreased relaxation responses, and decreased inhibition of platelet aggregation and adhesion. Methylene blue inhibits vascular responses not only in vitro but also in vivo. 205 -245 ' 246 The most important requirement for any biological interaction of agonist with its receptor is access of the agonist to its receptor. In the case of EDNO this becomes critically important because the agonist is formed in and released from one cell and must interact with intracellular receptors located within an adjacent cell. Thus, there must be cellto-cell communication. The mechanism for this is simple diffusion, which is a relatively rapid process for NO because of its lipophilicity and small molecular size. After release from endothelium, NO can easily and rapidly diffuse into nearby vascular smooth muscle cells and circulating or adhering platelets. Thus, NO possesses the biological properties of an autacoid in mediating local vascular and platelet responses through rapid cell-to-cell communication.
Although the evidence is substantial that at least one form of arterial and venous EDRF from certain vascular beds is one and the same substance and that this substance is NO or a labile nitroso compound, little is known about the formation, storage, and release of EDNO. EDNO can be derived from L-arginine, 239 and it is likely that EDNO is inactivated by spontaneous oxidation to nitrite and nitrate. Only little is known about the physiological and pathophysiological roles of EDNO or other EDRFs or the implications of decreased generation of EDRFs in cardiovascular disease. The demonstration that EDNO and prostacyclin are coreleased from endothelial cells by diverse stimuli and that both inhibit platelet function in a synergistic m a n n e r -suggests that the release and action of two different mediators with similar actions can amplify cellular function. There is no evidence, however, that EDNO and prostacyclin can evoke vascular smooth muscle relaxation in a synergistic manner.
An important question that awaits resolution is whether or not multiple EDRFs besides NO and prostacyclin exist. Such substances will need to be isolated and identified chemically just as has been performed for NO and prostacyclin. This may prove to be equally as arduous a task, especially if other EDRFs are unstable free radicals. There is evidence that oxygen radicals mediate cerebral arteriolar dilation by arachidonic acid and bradykinin in the cat 249 -250 and by bradykinin in the mouse. 251 Hydroxyl radical has been proposed to mediate bradykinin-elicited, endothelium-dependent relaxant responses in pial arterioles. 249 
